<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the immunocompromised patient with fever and pulmonary infiltrates</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the immunocompromised patient with fever and pulmonary infiltrates</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the immunocompromised patient with fever and pulmonary infiltrates</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jay A Fishman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The spectrum of immunocompromised hosts has expanded with prolonged survival of solid organ and hematopoietic cell transplant recipients, patients with immune deficiencies (including congenital disorders and HIV/AIDS), and autoimmune disorders, as well as the development of novel cancer therapies including immunotherapies and checkpoint inhibitors. Novel immunosuppressive therapies create a diverse set of immune deficits that create the substrate for opportunistic infections. Compared with immunologically normal hosts, these patients are defined by susceptibility to infection with organisms of otherwise low native virulence or by increased severity of common infections. Survival has improved with the availability of newer antimicrobial agents but is threatened by the emergence of antimicrobial resistance.</p><p>The approach to the immunocompromised patient with fever and pulmonary infiltrates will be reviewed here. An overview of pulmonary infections in immunocompromised hosts is presented separately. Empiric therapy for adult patients with fever and neutropenia is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a> and  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a> and  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Pulmonary infection is the most common tissue-invasive infection in immunocompromised patients [<a href="#rid1">1-7</a>]; early diagnosis and directed treatment are the cornerstones of successful management. The general rule is to be aggressive in pursuing a specific microbiologic diagnosis in immunocompromised patients with pulmonary infiltrates to enable early therapy while avoiding overly broad antimicrobial therapy. A specific diagnosis avoids the potential toxicities of broad-spectrum antimicrobial therapies, most notably nephrotoxicity, drug interactions, and <em>Clostridioides</em> <em>difficile</em> colitis. Invasive diagnostic techniques are often required.</p><p>Several general principles are useful for the evaluation of immunocompromised patients presenting with fever and pulmonary infiltrates.</p><p class="bulletIndent1"><span class="glyph">●</span>Most immunocompromised patients with any signs of possible invasive infection should be hospitalized for evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Awareness of the epidemiology of infection in the community (eg, respiratory viruses, tuberculosis) and the individual (eg, travel history, sexual history, prior infections, occupational exposures) provide helpful clues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple simultaneous pulmonary processes occur often. These include infectious (eg, viral, bacterial, fungal, parasitic) and noninfectious (eg, pulmonary edema, malignancy) etiologies. Routine chest radiography and sputum sampling may fail to detect these concomitant diseases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic testing is generally not useful in the acute management of immunocompromised patients. These patients often fail to generate an adequate or timely antibody response to infection. Microbiologic testing should include antigen detection and/or nucleic acid detection-based assays as well as cultures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence or absence of pulmonary infiltrates should be defined by chest imaging. A routine chest radiograph may be insufficient to exclude pulmonary involvement if there are respiratory symptoms or historical features that suggest a possible pulmonary process. Minor abnormalities on a chest radiograph in the immunocompromised host merit further evaluation, generally including computed tomography scanning. Comparison with prior imaging studies is essential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients, radiographic evidence of pneumonitis may appear or intensify with immune reconstitution, notably engraftment after neutropenia. In such patients, there are few data to guide decisions regarding empiric antimicrobial therapies [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After obtaining microbiologic samples, empiric antimicrobial therapy is initiated and is continued until specific microbiologic data are available to guide therapy. If anticipated invasive studies are delayed, empiric therapy should be instituted promptly after blood, urine, and sputum samples are obtained. Immediate empiric therapy is also appropriate for individuals who are clinically unstable, notably for those with hypotension, hypoxemia or progressive pulmonary processes, altered mental status or meningitis, evolving skin lesions, bleeding diathesis, or severe hyperglycemia. Antimicrobial agents used for prophylaxis should be avoided in empiric therapy. Specific guidelines such as those for fever and neutropenia must be modified based on physical and radiologic findings and past medical history, including exposures, previous infections, and prior antimicrobial therapies. (See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY AND RISK OF PNEUMONIA</span><span class="headingEndMark"> — </span>The incidence and severity of pneumonia vary with the characteristics of the affected individual, including the nature and duration of any immune deficits  (<a class="graphic graphic_table graphicRef57336" href="/z/d/graphic/57336.html" rel="external">table 1</a>) and epidemiologic exposures. The epidemiology and risk for pneumonia in immunocompromised hosts have shifted with the increased intensities of chemotherapeutic and/or immunosuppressive regimens and with patterns of antimicrobial use. Routine prophylaxis has increased the risk for unusual pathogens that are resistant to prophylactic agents including fluoroquinolone-resistant streptococci, other multidrug-resistant bacteria, azole-resistant molds, and ganciclovir-resistant cytomegalovirus (CMV) [<a href="#rid6">6,9,10</a>]. As a result, empiric therapies for infection require use of agents not used for prophylaxis in the recent past and review of prior microbiology data from individual patients.</p><p class="headingAnchor" id="H4"><span class="h2">Neutropenia</span><span class="headingEndMark"> — </span>Neutropenia is the most common risk factor for pulmonary infection in immunocompromised patients. Whether due to underlying malignancy, chemotherapy, or the side effects of other drugs, the depth and duration of neutropenia are correlated with the risk for infection [<a href="#rid11">11</a>].</p><p>Rates of infection vary depending upon the host and increase with the duration of neutropenia. Nosocomial infections in neutropenic cancer patients occur at a rate of 46.3 episodes per 1000 neutropenic days (48.3 episodes per 100 neutropenic patients) [<a href="#rid12">12</a>]. The rate of infection was similar in a study that included patients with acute leukemia, non-Hodgkin's lymphoma, or after conditioning for hematopoietic cell transplantation (37.7 episodes per 1000 neutropenic days), although over 64 percent of patients had febrile episodes while neutropenic [<a href="#rid13">13</a>]. The risk for infection increases in the neutropenic host in patients unable to achieve disease remission (eg, for acute leukemia) [<a href="#rid14">14</a>]. Rates of infection in solid tumor patients and solid organ transplant recipients are somewhat less.</p><p>The originating site of infection frequently cannot be identified in febrile cancer patients [<a href="#rid15">15-17</a>]. When identified, common sources of infection in the febrile neutropenic patient are colonizing organisms from the upper and lower respiratory tract especially with mucositis and aspiration, the gastrointestinal tract (including the perineal and perirectal areas), the urinary tract, and the skin (including intravenous lines and wounds) [<a href="#rid6">6,18,19</a>]. Pulmonary infections are among the leading causes of morbidity and mortality in febrile neutropenic patients [<a href="#rid20">20</a>]. Many infections are detected only at autopsy, particularly disseminated fungal or combined fungal and bacterial infections [<a href="#rid21">21-23</a>].</p><p>Mismatched allogeneic hematopoietic cell transplant recipients (eg, umbilical cord blood or matched unrelated donor transplants) being treated for hematologic malignancies require intensive induction chemotherapy, which may result in prolonged neutropenia. Such patients also require immunosuppression to prevent or treat graft-versus-host disease (GVHD). These patients are at particularly high risk of infection, often with organisms resistant to prophylactic agents. Breakthrough invasive fungal infection may occur despite prophylaxis [<a href="#rid24">24,25</a>]. Noninfectious pulmonary syndromes are notable in pre-engraftment or marrow recovery phases including idiopathic pneumonia syndrome, pulmonary hemorrhage (sometimes with <em>Stenotrophomonas maltophilia</em> in hematopoietic cell transplantation [<a href="#rid26">26</a>]), and engraftment syndrome, which is increased in those receiving hematopoietic growth factors [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H354232681"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids play an important role in the pathogenesis of pneumonia due to depression of phagocytic function of alveolar macrophages and neutrophils, decreased mobilization of inflammatory cells into areas of infection, and alterations in antigen presentation and lymphocyte mobilization. These effects increase the risk of bacterial and fungal infections (including those due to <em>Pneumocystis jirovecii</em>, <em>Nocardia </em>spp, and <em>Aspergillus </em>spp) and the risk for pulmonary involvement in the setting of certain herpes virus infections (eg, CMV, varicella zoster virus) [<a href="#rid29">29</a>]. A meta-analysis of 42 observational studies described a dose-dependent increase in serious infection risk of 1.5- to 4-fold for glucocorticoid doses of &lt;5 mg to &gt;20 mg/day [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a>.)</p><p class="headingAnchor" id="H354232721"><span class="h2">T cell suppression and lymphocyte depletion</span><span class="headingEndMark"> — </span>Use of T lymphocyte-depleting agents has increased the risk of certain infections based on the prolonged duration of lymphocytopenia and, depending on the preparation used, depletion of other cell types (eg, NK cells, B-lymphocytes). The most common infections in patients receiving these agents are those due to reactivation of latent herpesviruses as well as mold infections [<a href="#rid4">4,7,31</a>]. B lymphocyte depletion is used in the treatment of certain hematologic malignancies and various antibody depletion strategies (eg, plasmapheresis, proteasome inhibition, <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a>) for antibody-mediated rejection of transplanted organs and may predispose to infection due to encapsulated bacteria [<a href="#rid32">32</a>].</p><p>The agents used to suppress T lymphocyte function include the calcineurin inhibitors (eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) and mammalian target of rapamycin (mTOR) inhibitors (eg, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) used in organ and hematopoietic cell transplantation. These predispose to herpesvirus infections (CMV, herpes simplex, and varicella-zoster) and community-acquired respiratory viruses, fungal infections (including <em>Cryptococcus</em>, <em>Pneumocystis</em>, and <em>Aspergillus</em> spp), and parasites (eg, <em>Strongyloides</em>, <em>Toxoplasma,</em> and <em>Trypanosoma cruzi</em>) [<a href="#rid7">7,33-37</a>]. CMV infection predisposes to fungal infections including <em>Pneumocystis</em> and <em>Aspergillus </em>[<a href="#rid38">38</a>]. <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">Fludarabine</a> produces a prolonged deficit in T cell functions. mTOR inhibitors are associated with a form of pneumonitis, often in association with community acquired viral infections [<a href="#rid39">39</a>]. This syndrome presents with dyspnea and cough with interstitial pneumonitis and fibrosis and, occasionally, alveolar hemorrhage. Malignancies related to viral activation (eg, Epstein Barr virus-associated posttransplant lymphoproliferative disorder, skin cancers, anogenital cancer) are common complications of these agents [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H2430687019"><span class="h2">Transplantation</span><span class="headingEndMark"> — </span>The risk of infection in solid organ and hematopoietic cell transplant recipients is reviewed in detail separately, driven largely by T cell suppression [<a href="#rid4">4,7,33,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Autoimmune and inflammatory conditions</span><span class="headingEndMark"> — </span>Patients with autoimmune diseases, antibody deficiencies (eg, glomerulonephritis with proteinuria, Goodpasture syndrome, or receipt of chimeric antigen receptor-modified T [CAR-T] therapy), and some hematologic malignancies are susceptible to bacterial infections (ie, bacteremia) and to a lesser extent to opportunistic infections similar to those of cancer and transplant patients. Infections (eg, <em>Pneumocystis</em>, <em>Nocardia</em> spp) may result from deficiencies in opsonization and phagocytosis, notably during corticosteroid or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapies. The severity and nature of infection depend on the type, duration, and intensity of immunosuppressive therapy. The spectrum of opportunistic infections seen in this patient population is widening as the number and variety of immunosuppressive agents used to treat autoimmune diseases has increased, ranging from calcineurin inhibitors, anti-TNF alpha and anti-interleukin 6 (IL-6) agents, costimulatory blockade, Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors, and other biologic agents.</p><p>In patients with primary connective tissue/collagen vascular diseases (eg, granulomatosis with polyangiitis), infection may be difficult to distinguish from the effects of the primary disease or toxicities of therapy. Pulmonary manifestations of these diseases are discussed below. (See <a class="local">'Other mimics of infection'</a> below.)</p><p class="headingAnchor" id="H3637130699"><span class="h2">Checkpoint inhibitors and CAR-T cells</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors (ICIs) and targeted chimeric antigen receptor-modified T (CAR-T) cells can cause systemic immune-related adverse events (irAEs), which mimic or amplify infectious syndromes, including pneumonitis [<a href="#rid41">41</a>]. Differentiating irAEs from infection is often challenging [<a href="#rid35">35-38,42-44</a>].</p><p>Cell surface "immune checkpoint receptors" normally prevent nonspecific or excessive activation of T cells including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) or PD-1 ligands (PD-1L). Antibodies targeting these molecules upregulate endogenous immune responses. Following adoptive cell transfer of genetically engineered immune effector cells such as T lymphocytes carrying receptors for tumor antigens (CAR-T cells), CAR-T cells proliferate, kill tumor cells, and provide long-term surveillance. However, these therapies can be associated with profound inflammatory responses that can be difficult to distinguish from infection. Toxicities vary by agent and may manifest weeks to months after initial treatment [<a href="#rid42">42-44</a>].</p><p>Infections following CAR-T cell therapy are most often related to cytopenia from prior cancer therapies or following glucocorticoid, IL-6 inhibitor, and/or TNF-alpha inhibitor treatment for cytokine release syndrome (CRS) [<a href="#rid45">45,46</a>]. CAR-T cell therapy can be associated with B cell aplasia and hypogammaglobulinemia. As with other immunosuppressive treatments, infections that occur early after therapy are often nosocomial, whereas those that occur later can be opportunistic related to prolonged immune defects. In one case series evaluating 53 patients treated with CD19 CAR-T cell therapy for relapsed acute B cell leukemia, treatment was complicated by infection in 22 patients (42 percent) in the first 30 days following therapy [<a href="#rid46">46</a>]. A total of 26 infections were reported, 17 bacterial, 4 fungal, and 5 viral, occurring at a median of 18, 23, and 48 days post-CAR-T cell infusion, respectively. Three of 53 patients (6 percent) died from infection. Grade ≥3 CRS was independently associated with risk of infection (adjusted hazard ratio 2.67; 95% CI 1.0-7.3); whether the increased infectious risk was related to immunosuppressive therapies used to treat high-grade CRS is unclear.</p><p class="headingAnchor" id="H1344970435"><span class="h2">Biologic agents and targeted therapies</span><span class="headingEndMark"> — </span>Inhibitors of tumor necrosis factor (TNF)-alpha and blockade of other mediators of inflammation (cytokines and chemokines) predispose to infection with intracellular pathogens (mycobacteria, Legionella species) as well as systemic viral and fungal infections, including those caused by molds (<em>Aspergillus</em> spp), yeasts (<em>Cryptococcus </em>spp), dimorphic fungi (<em>Histoplasma capsulatum</em>, <em>Coccidioides </em>spp), and <em>P. jirovecii </em>[<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p>Certain cancer therapies such as <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> have unique cellular targets (Bruton’s tyrosine kinase in B-cell malignancies) and are associated with an excess incidence of invasive fungal infections [<a href="#rid48">48</a>]. Inhibitors of cytokine-mediated cell processes including the JAK/STAT pathway are achieving broad use in oncology and in autoimmune and inflammatory diseases. Use of these agents in organ transplantation resulted in increased rates of infection and post-transplant lymphoproliferative disorder compared with calcineurin inhibitor-based immunosuppression [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1418604"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>Pulmonary infections associated with HIV infection are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3716.html" rel="external">"Bacterial pulmonary infections in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3714.html" rel="external">"Toxoplasma pneumonia and other parasitic pulmonary infections in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p class="headingAnchor" id="H1093746650"><span class="h2">Concomitant viral infection</span><span class="headingEndMark"> — </span>The observation that pulmonary or systemic viral infection is associated with subsequent pneumonia has been described best for cytomegalovirus (CMV), influenza, and severe acute respiratory syndrome coronavirus 2. Factors that predispose to superinfection vary with the specific virus and include systemic and local immune responses (eg, in the lung transplant recipient), decreased mucociliary function, impaired recruitment of and phagocytosis by macrophages and neutrophils, neutropenia, or injury to type 2 pneumocytes [<a href="#rid50">50</a>]. Thus, pulmonary fungal infections (eg, <em>Pneumocystis pneumonia</em>, <em>Aspergillosis</em>) are not uncommon in the weeks following viral infection. Increased rates of nosocomial bacterial and mold infections have also been observed in patients on assisted ventilation with coronavirus disease 2019 pneumonia, generally in the setting of glucocorticoid and other immune modulatory therapies [<a href="#rid51">51</a>].  </p><p class="headingAnchor" id="H7"><span class="h1">ETIOLOGY OF PULMONARY INFILTRATES</span><span class="headingEndMark"> — </span>Infectious and noninfectious causes of pulmonary infiltrates may coexist in immunocompromised hosts.</p><p class="headingAnchor" id="H8"><span class="h2">Infection</span><span class="headingEndMark"> — </span>The etiology of infectious pneumonitis in immunocompromised patients, when documented, is diverse [<a href="#rid2">2,3,40,52-59</a>]. The spectrum of infection is altered by antimicrobial prophylaxis. The frequency of identification of common organisms varies with the nature of the host and with the aggressiveness of diagnostic approach. In one series using invasive diagnostic approaches for pulmonary infiltrates in immunocompromised hosts, a specific diagnosis was obtained in 162 of the 200 cases evaluated (81 percent) [<a href="#rid60">60</a>]. An infectious etiology was found in 125 patients (77 percent) and a noninfectious etiology in 37 (23 percent); 38 (19 percent) remained undiagnosed. Among infectious causes, bacteria were documented in 24 percent, fungi in 17 percent, and viruses in 10 percent. In 7 percent, the etiology was polymicrobial. There were no statistically significant associations between the specific underlying immunosuppressive state and the etiology of the pulmonary infiltrates. Overall, including both invasive and noninvasive approaches to diagnosis, approximate rates of infection include [<a href="#rid60">60-62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional bacteria – 37 percent (higher with neutropenia and mucositis and early after lung transplantation)</p><p class="bulletIndent1"><span class="glyph">●</span>Fungi – 14 percent (higher with prolonged neutropenia)</p><p class="bulletIndent1"><span class="glyph">●</span>Viruses – 15 percent (common with T cell suppression)</p><p class="bulletIndent1"><span class="glyph">●</span><em>P. jirovecii</em> (formerly <em>P. carinii</em>) – 5 to 15 percent (without prophylaxis)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Nocardia </em>spp – 7 percent (including sulfa-resistant strains)</p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium tuberculosis</em> – 1 percent (higher in endemic regions)</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed infections – 20 percent</p><p></p><p>The spectrum of pulmonary fungal infection includes infection with non-fumigatus <em>Aspergillus</em> spp, <em>Fusarium </em>spp, <em>Scedosporium </em>spp, and the Mucorales in patients with neutropenia and/or in association with graft-versus-host disease (GVHD) [<a href="#rid35">35,63,64</a>]. Azole-resistant mold infection may emerge during therapy  (<a class="graphic graphic_diagnosticimage graphicRef122477" href="/z/d/graphic/122477.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a> and  <a class="medical medical_review" href="/z/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a> and  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p>Mixed infections with combinations of respiratory viruses, cytomegalovirus (CMV), <em>Aspergillus</em> spp, and/or gram-negative bacilli are common in neutropenic hosts and hematopoietic cell transplant (HCT) recipients [<a href="#rid65">65-69</a>]. <em>Pneumocystis </em>pneumonia (PCP) is most common in patients receiving glucocorticoids as a part of a chemotherapeutic or maintenance regimen [<a href="#rid38">38</a>].</p><p>Invasive CMV disease may be difficult to distinguish from viral shedding (or activation in the setting of severe systemic illness) in the immunocompromised host with pulmonary infiltrates. Confirmation of invasive CMV pneumonitis can be achieved using assays from blood samples (eg, CMV viral load by nucleic acid testing) and/or tissue histology  (<a class="graphic graphic_diagnosticimage graphicRef65546" href="/z/d/graphic/65546.html" rel="external">image 2</a>). In HCT recipients, CMV pneumonitis occurs most commonly in seropositive individuals (CMV donor seronegative, recipient seropositive; CMV D-/R+) after the completion of prophylaxis (late infection) [<a href="#rid70">70,71</a>]. This contrasts with the risk profile of CMV pneumonitis in solid organ transplantation, which is greatest in seronegative recipients of seropositive organs (CMV D+/R-). Antiviral resistance may allow CMV infection to break through antiviral prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection"</a>.)</p><p class="headingAnchor" id="H1420650"><span class="h3">The lungs in systemic infections</span><span class="headingEndMark"> — </span>Some infections, especially those due to tuberculosis, <em>Nocardia</em> spp, and <em>Cryptococcus</em> spp, generally enter via the lungs but metastasize to other sites. These other sites may be more accessible than the lungs for establishing a microbiologic diagnosis. (See <a class="local">'Skin and CSF sampling'</a> below.)</p><p>The lungs can also be a site for hematogenous spread of infection (eg, septic emboli due to <em>Staphylococcus aureus</em> or gram-negative bacteremia). Peripheral pulmonary lesions in the lungs can be a clue that there is important disease elsewhere (eg, line sepsis, hepatosplenic candidiasis, infective endocarditis)  (<a class="graphic graphic_diagnosticimage graphicRef76610" href="/z/d/graphic/76610.html" rel="external">image 3</a>).</p><p class="headingAnchor" id="H9"><span class="h2">Noninfectious</span><span class="headingEndMark"> — </span>Noninfectious etiologies for pulmonary infiltrates are common in immunocompromised patients, including pulmonary embolus, tumor, radiation pneumonitis, cancer, fibrosis, atelectasis with pulmonary edema, drug allergy or toxicity, and pulmonary hemorrhage [<a href="#rid72">72-74</a>]. Often, the resolution of fever in response to a trial of antibiotics is the only evidence suggesting that infection was present.</p><p>In an older series of patients who underwent open lung biopsy at Memorial Sloan Kettering Cancer Center, inflammatory processes (such as bronchiolitis obliterans organizing pneumonia [BOOP] or drug toxicity) and malignancy accounted for 67 percent of the specific diagnoses made; the remaining 33 percent were due to infection [<a href="#rid75">75</a>]. Drug toxicities (<a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and sulfonamides), leukoagglutinin reactions, radiation injury, pulmonary emboli, pulmonary hemorrhage, and cancer metastases may coexist with opportunistic infections.</p><p class="headingAnchor" id="H10"><span class="h3">Radiation-induced injury</span><span class="headingEndMark"> — </span>Clinically apparent injury due to radiation therapy can occur acutely (typically 4 to 12 weeks following irradiation) or more than six months after the initial exposure to a dose of &gt;2000 rads. Vascular damage, mononuclear infiltrates, and edema are seen histologically at 3 to 12 months. The severity of lung injury due to drugs or radiation appears to correlate with the rapidity of the withdrawal of glucocorticoid therapy. However, this timing may also reflect the emergence of the underlying inflammatory response rather than enhanced injury. Radiation fibrosis may occur (usually after six to nine months) and will amplify radiologic findings with other processes; lung function may not stabilize for up to two years. (See  <a class="medical medical_review" href="/z/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Drug-induced injury</span><span class="headingEndMark"> — </span>Acute, drug-induced lung disease may reflect hypersensitivity to chemotherapeutic agents, sulfonamides, or other agents.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, and <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">procarbazine</a> can cause a syndrome of nonproductive cough, fever, dyspnea, and pleurisy with skin rash and blood eosinophilia. Chest radiographs generally demonstrate diffuse reticular infiltrates. (See  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> may cause a syndrome of pulmonary disease with interstitial inflammation and pulmonary fibrosis that occurs subacutely over weeks to months. (See  <a class="medical medical_review" href="/z/d/html/4349.html" rel="external">"Cyclophosphamide pulmonary toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> (rapamycin) used for immune suppression may be associated with a form of interstitial pneumonitis in transplant recipients [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Rapamycin and analogs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other common drugs causing lung injury include <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>, but fever is less often associated with these other drug-induced forms of pneumonitis.</p><p></p><p>Drug toxicity may be related to the cumulative dose of the agent (eg, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> over 450 mg, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> [BCNU], <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">lomustine</a> [CCNU]) and to the age of the patient. Synergistic pulmonary toxicity is seen when certain chemotherapeutic agents are used in combination with radiation therapy (eg, bleomycin, <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>) or oxygen (bleomycin).</p><p class="headingAnchor" id="H503786756"><span class="h3">Idiopathic pneumonia syndrome</span><span class="headingEndMark"> — </span>The idiopathic pneumonia syndrome (IPS) is an important noninfectious complication of HCT, which typically occurs within the first several weeks following transplant [<a href="#rid77">77</a>]. IPS is less common following nonmyeloablative HCT. IPS is a clinical syndrome characterized by widespread alveolar injury plus signs and symptoms of pneumonia plus evidence of abnormal pulmonary physiology (an increased alveolar-arterial oxygen gradient or the need for supplemental oxygen) in the absence of lower respiratory tract infection. IPS may represent a heterogeneous group of disorders that result in the common pathologic findings of interstitial pneumonitis and/or diffuse alveolar damage. (See  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Idiopathic pneumonia syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation", section on 'Early complications (first month)'</a>.)</p><p class="headingAnchor" id="H503786769"><span class="h3">Engraftment syndrome</span><span class="headingEndMark"> — </span>The engraftment syndrome is generally suspected when a patient develops fever and rash approximately 9 to 16 days following autologous HCT (and more rarely following allogeneic HCT) [<a href="#rid27">27</a>]. The engraftment syndrome is associated with increased systemic capillary permeability that occurs during the neutrophil recovery phase. It is attributed to release of proinflammatory cytokines that precedes neutrophil engraftment. Clinical manifestations include fever without infection, maculopapular rash mimicking acute GVHD, diffuse pulmonary opacities, and/or diarrhea. (See  <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation", section on 'Engraftment syndrome and PERDS'</a> and  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Engraftment syndrome'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Other mimics of infection</span><span class="headingEndMark"> — </span>A variety of other noninfectious processes can mimic infection in immunocompromised patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary edema or bleeding. (See  <a class="medical medical_review" href="/z/d/html/3487.html" rel="external">"Pathophysiology of cardiogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/z/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">"The diffuse alveolar hemorrhage syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alveolar proteinosis may be associated with hematologic malignancies or can coexist with infection due to <em>S. maltophilia</em>, <em>Nocardia</em>, PCP, or less often with cryptococcosis, aspergillosis, tuberculosis, or histoplasmosis [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">"Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary infarction can also resemble infection; chest radiographs tend to have segmental pleural-based infiltrates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with primary connective tissue/collagen vascular diseases, infection may be difficult to distinguish from the effects of the primary disease or toxicities of therapy. Systemic lupus erythematosus and rheumatoid arthritis are associated with a variety of pulmonary infiltrates. The pulmonary-renal syndromes (Goodpasture syndrome and granulomatosis with polyangiitis) may present with pulmonary hemorrhage, consolidation, nodular lesions, and patchy infiltrates and may progress to cavitation. Sarcoidosis is generally associated with hilar lymph node enlargement and interstitial infiltrates, but nodular disease and superinfection are common. Histology may be required to differentiate infection from noninfectious pulmonary processes. (See  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4330.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older therapies for rheumatic disease (eg, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, gold salts, antiinflammatory agents) may cause acute or chronic reticulonodular pulmonary infiltrates associated with fever, dyspnea, and cough. Anti-tumor necrosis factor-alpha therapy has been associated with the reactivation of latent intracellular infections including tuberculosis and histoplasmosis. (See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory distress syndrome (ARDS) is usually the result of severe pneumonia or ongoing systemic infectious or inflammatory processes. Systemic inflammation syndromes associated with CAR-T cells or immunotherapy, severe acute respiratory syndrome coronavirus 2 infection, or sepsis are indistinguishable as a prelude to ARDS. (See  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion-associated leukoagglutinin reactions (transfusion-related lung injury [TRALI]) are uncommon, but transient pulmonary infiltrates may occur following transfusions. Virtually all blood products have been implicated in TRALI. Infusions of whole blood, platelets, packed red blood cells, and fresh frozen plasma are the most commonly identified precipitating causes, but case reports have also implicated transfusions of allogeneic stem cells, cryoprecipitates, intravenous immunoglobulin, and granulocytes. (See  <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allograft rejection, chronic lung allograft dysfunction (CLAD), or primary graft dysfunction in lung transplant recipients can also mimic pulmonary infection. (See  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posttransplant lymphoproliferative disorders may present with pulmonary nodules or lymphadenopathy. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bronchiolitis obliterans (BOS) following allogeneic HCT is associated with GVHD, antecedent respiratory viral infections, advanced age, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> exposure, and low immunoglobulin levels. BOS is also observed in CLAD. Pulmonary venoocclusive disease may present with dyspnea, elevated pulmonary arterial pressures, and the appearance of pulmonary edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Checkpoint inhibitor therapy may cause pneumonitis in up to 6 percent of patients receiving programmed cell death receptor 1 (PD-1) or PD-1 ligand (PD-1L) antagonists and up to 12 percent with combined PD-1/PD-1L and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade [<a href="#rid78">78-80</a>]. Pneumonitis may progress to acute respiratory distress syndrome. Pulmonary immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy have a median onset of three months but may occur within a week [<a href="#rid81">81,82</a>]. PD-1/PD-1L therapies are more often associated with pneumonitis (or thyroiditis) than CTLA-4 antibodies. Pneumonitis may occur with or without other irAEs including mild skin, endocrine, or autoimmune manifestations or severe inflammatory processes including colitis, myocarditis, or shock. Immune activation may also unmask subclinical infections, and combinations of immune and infectious etiologies may occur (eg, allergic bronchopulmonary aspergillosis). A grading system exists for lung toxicities based on symptoms and radiologic data [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CAR-T cell therapies may induce toxicities including cytokine-release syndrome with fevers and multiorgan dysfunction, CAR-T cell-related encephalopathy syndrome with altered mental status and neurologic dysfunction, or hemophagocytic lymphohistiocytosis-macrophage-activation syndrome [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Recognition of infection in immunocompromised hosts is often delayed because the usual signs of infection are missing due to the muted inflammatory response. As an example, sputum production and radiographic changes may be absent in the neutropenic patient with pneumonia. In one series of cancer patients with pneumonia, neutropenic patients produced purulent sputum far less often than those without neutropenia (8 versus 84 percent) [<a href="#rid58">58</a>]. Many infections are recognized only when fever, clinical symptoms (eg, cough, pleurisy, confusion), unexplained hypotension, or radiologic abnormalities develop after immune suppression or neutropenia is reversed. Blood, urine, and sputum cultures (and cerebrospinal fluid if relevant) should be obtained before starting antimicrobial therapy.</p><p class="headingAnchor" id="H1420151"><span class="h2">Hospital admission</span><span class="headingEndMark"> — </span>The need for hospitalization is among early management decisions regarding immunocompromised patients with pneumonitis and possible infection. Any sign of invasive infection in immunocompromised patients requires at least a brief hospitalization. Localizing signs (eg, headache, altered mental status, rash, dyspnea, chest pain, redness or pain over an indwelling catheter site, pulmonary infiltrates) merit consideration for emergency admission. While symptoms may be muted, a low threshold for hospitalization must exist if the patient “looks sick.” Immunocompromised patients with fever without a clear etiology are at high risk for rapid progression.</p><p>Certain subgroups of immunocompromised patients are highly susceptible to infection. Symptoms may continue to evolve despite therapy. These include patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive tumors (eg, new or relapsed leukemia or lymphoma or uncontrolled metastatic cancer)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent hematopoietic cell transplant recipients, especially those with severe graft-versus-host disease, or delayed engraftment, such as after umbilical cord blood transplantation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent infections, especially due to cytomegalovirus (CMV) or respiratory viruses, or with known colonization with fungi or resistant bacteria [<a href="#rid84">84,85</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absolute neutrophil count (ANC) below 500/microL, and especially those below 100/microL, or those in whom the ANC is falling rapidly or expected to fall below 100/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-dose glucocorticoid therapy or recent intensification of immunosuppression (eg, in solid organ transplant recipients being treated for rejection)</p><p></p><p>These patients are best managed as inpatients until clinically stable. Patients with frank rigors or hypotension should be admitted. A very low threshold should also exist for admission of splenectomized patients with fever. Patients with a history of recent or recurrent infection after organ transplantation (eg, <em>Pseudomonas</em> spp or <em>S. maltophilia </em>infections in lung transplant recipients or CMV infection in any solid organ transplant recipient) or with anatomic predisposition to infection (eg, bronchiectasis) merit consideration for hospitalization. Patients with pneumonitis following checkpoint inhibitor therapy may progress over hours to days. </p><p class="headingAnchor" id="H18"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Since the differential diagnosis of pulmonary infiltrates in the immunocompromised host is broad, historical (eg, epidemiologic) and radiologic clues may be useful in narrowing the possibilities  (<a class="graphic graphic_table graphicRef73151" href="/z/d/graphic/73151.html" rel="external">table 2</a>). Molecular diagnostics and whole genome sequencing tools are valuable adjuncts to culture-based approaches. Nevertheless, sampling tissue is frequently required to make a definitive diagnosis, especially in distinguishing infectious from noninfectious causes.</p><p class="headingAnchor" id="H19"><span class="h2">Historical clues</span><span class="headingEndMark"> — </span>Historical features are often useful in making a preliminary diagnosis and in selecting the initial empiric antimicrobial regimen. Some of these include:</p><p class="bulletIndent1"><span class="glyph">●</span>Travel and occupation – Exposures to tuberculosis, endemic fungi (eg, <em>H. capsulatum</em>, <em>Coccidioides</em> spp), <em>Rhodococcus equi</em> (horse breeders), <em>Cryptococcus neoformans</em> (eg, pigeon breeders), <em>Strongyloides stercoralis</em> (residence in or prolonged travel to endemic areas, even quite distant in time), or exposure to soil (eg, <em>Aspergillus</em> spp or <em>Nocardia </em>spp in landscapers and gardeners)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged duration of neutropenia (higher risk for gram-negative infections, <em>Aspergillus</em> spp, and <em>Fusarium </em>spp)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Past history of frequent antimicrobial exposure (increased risk for organisms with resistance to antimicrobials used previously)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent intensification of immunosuppression for graft rejection (cytomegalovirus [CMV], <em>Pneumocystis</em>) or graft-versus-host disease (<em>Aspergillus</em> or molds) or change in prophylaxis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential or witnessed aspiration (risk for anaerobic infection)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of potential pulmonary pathogens in prior cultures, particularly molds (<em>Aspergillus</em> spp, <em>Fusarium </em>spp), <em>Pseudomonas</em> spp, or <em>Stenotrophomonas</em> spp</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac abnormalities (endocarditis), indwelling catheters, or intravascular clot (bacteremic seeding of the lungs)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstructing metastatic tumors, particularly intrathoracic malignancies (which can lead to postobstructive pneumonia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus with sinopulmonary infection (mucormycosis) (see  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The specific immune defects and their associated infections  (<a class="graphic graphic_table graphicRef57336" href="/z/d/graphic/57336.html" rel="external">table 1</a>)</p><p></p><p class="headingAnchor" id="H2028365813"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>The initial evaluation for immunocompromised patients with fever with or without pulmonary findings, at a minimum, should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid assessment of vital signs, including oxygen saturation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrolytes, blood urea nitrogen, and creatinine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood cultures (minimum of two sets, with at least one peripheral set and one set from any indwelling catheter)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine sediment examination and culture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sputum for Gram stain, fungal smears, and cultures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging of the lungs (chest radiography or, if possible, chest computed tomographic scanning) and imaging of any symptomatic site (eg, abdomen)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin examination, looking for evidence of metastatic infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMV quantitative molecular testing is often valuable; other viral polymerase chain reaction (PCR) assays as appropriate to the individual (adenovirus, parvovirus B19, severe acute respiratory syndrome coronavirus 2)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consideration of sample collection for nonculture-based diagnostic tools (eg, specific molecular and antigen tests such as <em>Aspergillus</em> or <em>Pneumocystis</em> PCR, cryptococcal antigen), <em>Aspergillus</em> galactomannan, beta-1,3,-glucan, whole genome sequencing) [<a href="#rid86">86</a>]</p><p></p><p class="headingAnchor" id="H1420612"><span class="h2">Hypoxemia</span><span class="headingEndMark"> — </span>The presence or absence of hypoxemia can assist in the differential diagnosis of pulmonary infiltrates in immunocompromised patients. Hypoxemia with an elevation in lactic dehydrogenase or beta-1,3-glucan and minimal radiographic findings are common in <em>Pneumocystis </em>pneumonia (PCP), whereas the absence of hypoxemia with pulmonary consolidation is more common in nocardiosis, tuberculosis, and fungal infections until later in the course.</p><p class="headingAnchor" id="H73875042"><span class="h2">Radiologic clues</span></p><p class="headingAnchor" id="H21"><span class="h3">Chest radiography</span><span class="headingEndMark"> — </span>The presence or absence of pulmonary infiltrates should be defined by chest radiography or computed tomography (CT) scan since the pattern of involvement can be helpful in establishing the etiology of the process [<a href="#rid87">87,88</a>]. A chest radiograph is insufficient to exclude pulmonary involvement if there are respiratory symptoms or historical features that suggest a possible pulmonary process. The threshold for obtaining a chest CT is very low. The initial findings and evolution of the chest radiograph provide important clues to both the differential diagnosis of pulmonary infection and the appropriate diagnostic evaluation  (<a class="graphic graphic_table graphicRef73151" href="/z/d/graphic/73151.html" rel="external">table 2</a>) [<a href="#rid89">89</a>]. The following radiographic parameters are useful in developing clinical-radiographic-pathologic correlations [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Time of appearance, rate of progression, and time to resolution of pulmonary radiographic abnormalities in relation to clinical events. Comparison with prior imaging results is essential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distribution of radiologic abnormalities – An abnormality confined to one anatomic area is considered focal, whereas widespread lesions are considered diffuse. Abnormalities that are present in more than one area but are discrete are termed multifocal. Findings may be located centrally, peripherally, or both, particularly on CT scans.</p><p></p><p>Three types of pulmonary infiltrates are common:</p><p class="bulletIndent1"><span class="glyph">●</span>Consolidation, with a substantial replacement of alveolar air by tissue density material, typically with air bronchograms and a peripheral location of the abnormality  (<a class="graphic graphic_diagnosticimage graphicRef80265" href="/z/d/graphic/80265.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peribronchovascular (or interstitial) distribution, in which the infiltrate is predominantly oriented along the peribronchial or perivascular bundles  (<a class="graphic graphic_diagnosticimage graphicRef66492" href="/z/d/graphic/66492.html" rel="external">image 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular space-occupying nonanatomic lesions with well-defined, more or less rounded edges surrounded by aerated lung</p><p></p><p>Other findings may include pleural fluid, atelectasis, cavitation  (<a class="graphic graphic_diagnosticimage graphicRef79874" href="/z/d/graphic/79874.html" rel="external">image 6</a>), lymphadenopathy, and cardiac enlargement. The location of pleural fluid can be a clue; bilateral effusions are more common in congestive heart failure and fluid overload, and unilateral in necrotizing or granulomatous infection (especially in association with lymphadenopathy or cavitation).</p><p>This classification system for radiographs can be combined with information about the rate of progression of the illness to generate a differential diagnosis. Several examples are illustrative:</p><p class="bulletIndent1"><span class="glyph">●</span>A focal or multifocal consolidation of acute onset will probably be caused by a bacterial infection. In contrast, similar multifocal lesions with a subacute to chronic progression are more commonly due to fungal, tuberculous, or nocardial infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large nodules are usually a sign of fungal or nocardial infection in this patient population, particularly if they are subacute to chronic in onset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute disease with diffuse abnormalities, either of the peribronchovascular type or miliary micronodules, are usually caused by viruses (especially CMV or respiratory viruses), <em>P. jirovecii</em>, or, in the lung transplant recipient, rejection  (<a class="graphic graphic_diagnosticimage graphicRef66794" href="/z/d/graphic/66794.html" rel="external">image 7</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of cavitation suggests a necrotizing infection, which can be caused by filamentous fungi, <em>Nocardia</em> spp, mycobacteria, certain gram-negative bacilli (most commonly <em>Klebsiella pneumoniae</em> and <em>Pseudomonas aeruginosa</em>), and anaerobes [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The appearance of invasive pulmonary aspergillosis is heterogeneous [<a href="#rid90">90</a>]. The most common features include patchy infiltrates, nodules, cavitation, and pleural-based wedge-shaped lesions with associated pleurisy [<a href="#rid69">69</a>]. In some patients, including those with neutropenia, the initial appearance may be nodules with surrounding hypoattenuation (the "halo sign") followed by cavitation (the "air-crescent sign") following the return of neutrophils. The halo sign may also be observed with other infections that cause infarction (eg, other angioinvasive fungi, <em>Nocardia</em> spp, <em>P. aeruginosa</em>) and malignancies. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis", section on 'Imaging'</a>.)</p><p></p><p>The depressed inflammatory response of the immunocompromised transplant patient may modify or delay the appearance of a pulmonary lesion on radiography, especially if neutropenia is present. As an example, fungal invasion, which causes a less exuberant inflammatory response than does bacterial infection, will often be very slow to appear on conventional chest radiography. By contrast, immune reconstitution (eg, leukocytes after hematopoietic cell transplantation or chemotherapy or HIV therapy) or immune stimulation (with checkpoint inhibitors) may reveal previously unrecognized pulmonary infiltrates.</p><p>The following table reviews the radiographic appearances of pulmonary disorders in immunocompromised patients  (<a class="graphic graphic_table graphicRef73151" href="/z/d/graphic/73151.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H22"><span class="h3">Chest CT</span><span class="headingEndMark"> — </span>Computed tomography (CT) frequently reveals abnormalities even when the chest radiograph is negative or has only subtle findings. CT can also help to define the extent of the disease. Knowledge of the extent of infection at the time of diagnosis allows for subsequent assessment of the response to therapy. This is especially relevant for opportunistic fungal and nocardial infections. Therapy should be continued until evidence of infection is eliminated; reversal of immunosuppression may accelerate radiologic progression (immune reconstitution) while enhancing clinical recovery. (See  <a class="medical medical_review" href="/z/d/html/5513.html" rel="external">"Treatment of nocardiosis"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Duration'</a>.)</p><p>The morphology of the abnormalities found on CT scan can be useful in developing a differential diagnosis; few lesions are sufficiently specific to obviate the need for microbiologic diagnosis [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cavitary CT lesions are suggestive of infections with mycobacteria, <em>Nocardia </em>spp, <em>Cryptococcus </em>spp, <em>Aspergillus </em>spp, and some gram-negative bacilli (<em>P. aeruginosa</em>, <em>Klebsiella</em> spp).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapidly expanding pulmonary lesions with cavitation and/or hemorrhage are associated with the Mucorales, especially in diabetics, and <em>Scedosporium</em> spp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opacified secondary pulmonary lobules in the lung periphery are suggestive of bland pulmonary infarcts or septic or hemorrhagic <em>Aspergillus</em> infarcts (especially if cavitary).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opacities in a peribronchial (or interstitial) distribution are suggestive of fluid overload, viral infection such as CMV  (<a class="graphic graphic_diagnosticimage graphicRef50696" href="/z/d/graphic/50696.html" rel="external">image 8</a>), or <em>P. jirovecii</em> infection  (<a class="graphic graphic_diagnosticimage graphicRef58132" href="/z/d/graphic/58132.html" rel="external">image 9</a>), and, in the lung transplant recipient, allograft rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dense regional or lobar consolidation on CT is usually seen in bacterial pneumonia or invasive fungal infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy is not a common finding in immunosuppressed patients other than in those with lymphoma or posttransplant lymphoproliferative disorder associated with Epstein-Barr virus. Lymphadenopathy may be observed with some acute viral infections (CMV), sarcoidosis, and infections due to mycobacteria and <em>Cryptococcus</em> spp and with drug reactions (eg, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>). Positron emission tomography-CT (PET-CT) may differentiate infection from tumor.</p><p></p><p>In contrast with conventional radiographs, CT scans will frequently detect multiple patterns simultaneously, which can raise the possibility of dual processes (eg, fibrosis and infection) or sequential infections of the lungs. In a patient being treated for PCP, for example, the appearance of acinar, macronodular, or cavitary lesions is highly suggestive of a complicating infection, such as <em>Aspergillus</em> invasion of lung tissue compromised by the primary process.</p><p>Another important use of the CT scan is to identify the site for optimal sampling and assist in defining the most appropriate invasive procedure [<a href="#rid91">91</a>]. Thus, CT can provide precise guidance for needle biopsy or for thoracoscopic or open lung excision [<a href="#rid91">91-97</a>]. CT can also help to predict whether bronchoscopy is likely to be useful. As an example, the demonstration of a feeding bronchus that communicates with a pulmonary nodule greatly increases the diagnostic yield when bronchoscopy is performed (60 versus 30 percent when the feeding bronchus is not visible). If CT demonstrates centrally located diffuse opacities, a bronchoscopic approach is the procedure of choice.</p><p class="headingAnchor" id="H23"><span class="h2">Invasive procedures</span><span class="headingEndMark"> — </span>Invasive procedures are frequently required to obtain tissue or respiratory samples for specific diagnoses. Decisions regarding invasive procedures are best made early in the course; patients may become too ill or develop contraindications (eg, coagulopathy, hypoxemia) that prevent procedures [<a href="#rid60">60,62,98,99</a>].</p><p class="headingAnchor" id="H1420235"><span class="h3">Skin and CSF sampling</span><span class="headingEndMark"> — </span>As discussed above, several infections, especially those due to <em>M. tuberculosis</em>, <em>Nocardia </em>spp, and <em>Cryptococcus</em> spp, generally enter via the lungs but metastasize to other sites. These other sites may be more accessible than the lungs for establishing a microbiologic diagnosis. Thus, skin lesions or cerebrospinal fluid (CSF) may demonstrate <em>Cryptococcus </em>spp or mycobacterial infection before microbiologic data from sputum or lung biopsy specimens are available. (See <a class="local">'The lungs in systemic infections'</a> above.)</p><p class="headingAnchor" id="H1420242"><span class="h3">Lung sampling</span><span class="headingEndMark"> — </span>An invasive diagnostic procedure such as bronchoscopy with bronchoalveolar lavage (BAL) and/or transbronchial biopsy, percutaneous needle biopsy, video-assisted thorascopic biopsy (VATS), or open lung biopsy is frequently required to obtain a sample of sputum or lung tissue [<a href="#rid92">92-96,98-105</a>]. The selection of the optimal procedure is determined both by the nature (ie, focal or diffuse) and location of the pulmonary lesion and the skills available locally. Diffuse lesions may be sampled by transbronchial biopsy, whereas nodules are better located by CT-guided percutaneous needle biopsy, VATS, or open lung biopsy. VATS is also very useful for sampling of peripheral pulmonary lesions. The sensitivity of BAL is improved by early (days 1 to 2) over later sampling and is reduced by antimicrobial treatment [<a href="#rid98">98,105,106</a>]. The yield of invasive procedures varies between 25 and approximately 60 percent depending on the patient population studied. In 199 patients with hematologic malignancy and fever, BAL was performed 246 times and produced a microbiologic diagnoses in 118 patients [<a href="#rid107">107</a>].</p><p>It is reasonable to obtain an induced sputum for certain studies (eg, acid-fast bacilli, <em>Pneumocystis</em>, cytology, and routine stains and cultures) while awaiting more invasive procedures [<a href="#rid108">108</a>]. Positive results may allow for more invasive procedures to be avoided. The yield of induced sputum samples is higher than routine sputum samples only for mycobacteria, PCP, and cytology [<a href="#rid108">108</a>].</p><p>The diagnostic yield of BAL is greatest in untreated HIV-infected patients due to the large numbers of organisms (eg, <em>P. jirovecii</em>, mycobacteria) compared with other compromised individuals [<a href="#rid109">109</a>]. Conversely, transbronchial biopsy may be considered with BAL in HIV-uninfected immunocompromised hosts without specific contraindications to avoid the need for multiple sequential procedures. BAL alone is less often useful for the diagnosis of invasive fungal infection than for PCP or bacterial processes. BAL samples should be coupled to microbiologic studies (cultures, polymerase chain reaction, <em>Aspergillus</em> galactomannan antigen) to improve sensitivity [<a href="#rid110">110-112</a>]. Biopsy allows distinction between colonization and invasion of fungal or viral infections and may detect underlying processes such as bronchiolitis obliterans and drug-induced lung injury. Bronchial brushings do not generally add much information in immunocompromised patients. Post-BAL sputum samples are often revealing.  </p><p>In patients in whom transbronchial biopsy is not feasible, VATS or open lung biopsy will often provide the best means for establishing a diagnosis [<a href="#rid105">105,113</a>]. One study from Memorial Sloan Kettering Cancer Center evaluated the results of lung biopsy (either via thoracotomy or VATS) in 63 patients with hematologic malignancies: 40 percent of patients had active malignancy at the time of the procedure [<a href="#rid75">75</a>]. Only 6 percent of patients were neutropenic at the time of the biopsy. Open lung biopsy resulted in a specific diagnosis in 62 percent of these cases and in a change of therapy in 57 percent. Patients with focal abnormalities by chest radiography were more likely than those with diffuse findings to obtain a specific diagnosis following biopsy (79 versus 32 percent). Forty-six percent of patients who underwent bronchoscopy with BAL, 50 percent of the eight patients who underwent transbronchial biopsy, and 50 percent of patients who underwent needle aspiration had specific diagnoses made after lung biopsy. The procedure resulted in complications in 13 percent of cases, including two with major complications. However, the mortality was improved at 30 and 90 days post-procedure for those in whom a specific diagnosis was made compared with those without a specific diagnosis, especially in patients who had undergone hematopoietic cell transplantation (8 versus 62 percent 90-day mortality).</p><p class="headingAnchor" id="H24"><span class="h2">Microbiologic assays</span><span class="headingEndMark"> — </span>Routine sputum samples should be collected for cultures and staining whenever possible. Induced sputum specimens are most useful for diagnosing mycobacterial infections and PCP and for cytologic evaluation [<a href="#rid108">108</a>]. In many cases, bronchoscopy with BAL is required to obtain adequate specimens  (<a class="graphic graphic_table graphicRef70685" href="/z/d/graphic/70685.html" rel="external">table 3</a>) [<a href="#rid104">104</a>].</p><p>In addition to microbiologic testing of sputum samples, non-culture-based assays can be performed on a variety of other types of samples and can be used as adjuncts to culture-based techniques, although negative assays may not definitively exclude specific diagnoses:</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal washings or swabs (direct fluorescent antibody and viral cultures) may be used for the diagnosis of community-acquired viral infections due to influenza, parainfluenza, adenovirus, metapneumovirus, and respiratory syncytial virus.</p><p></p><p class="bulletIndent1">Testing for coronavirus disease 2019 (COVID-19) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary antigen tests may be used to diagnose <em>Legionella pneumophila</em>, <em>H. capsulatum</em>, <em>Blastomyces dermatitidis</em>, and <em>Streptococcus pneumoniae</em> infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Various antigen detection and nucleic acid-based assays can be performed using blood samples as well as CSF and BAL fluid. Examples include CMV viral loads (nucleic acid testing [NAT]) or antigenemia, serum cryptococcal antigen (particularly if any signs of meningitis), syphilis serology, human herpesvirus 6 NAT, <em>Aspergillus galactomannan</em> antigen [<a href="#rid111">111,114</a>], <em>Histoplasma</em> antigen, and 1,3-beta-D-glucan. The <em>A. galactomannan</em> antigen assay can also be performed on BAL samples.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular diagnostic techniques including nucleic acid amplification and unbiased (next-generation) metagenomic sequencing can be applied to tissue and respiratory specimens to identify unculturable pathogens [<a href="#rid86">86,115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Newer molecular diagnostic techniques may be applicable to BAL fluid.</p><p></p><p>Detection of certain common organisms (eg, <em>Aspergillus </em>spp, CMV) in respiratory tract specimens may represent colonization rather than infection. Thus, it is important to interpret positive test results in clinical context (eg, whether there is a compatible clinical syndrome and radiographic findings). The presence of CMV viremia may indicate CMV reactivation; viremia in the context of a compatible pulmonary syndrome is suggestive of invasive disease. The absence of CMV viremia may mitigate against the diagnosis of invasive CMV pneumonitis. (See  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"</a> and  <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection"</a>.)</p><p>The decision of which studies to obtain depends upon the individual patient's clinical findings and on availability at clinical laboratories.</p><p>Serologic techniques are generally of little use in the diagnosis of active infection in immunocompromised patients because such patients may be unable to generate an adequate immune response to a new pathogen or they may have made a response to a previous infection before they became immunocompromised. Thus, both a negative and a positive result may be uninterpretable.</p><p class="headingAnchor" id="H25"><span class="h2">Pursuit of a unifying diagnosis</span><span class="headingEndMark"> — </span>While it is always appealing to make a single diagnosis and initiate therapy, it is important to remember that multiple simultaneous processes are common in the immunocompromised patient. The occurrence of multiple simultaneous infections or conditions can complicate and delay appropriate therapy  (<a class="graphic graphic_diagnosticimage graphicRef60143" href="/z/d/graphic/60143.html" rel="external">image 10</a>). As an example, CMV infection may complicate the treatment of graft rejection or venoocclusive disease or contribute to the pathogenesis of PCP or <em>Aspergillus</em> pneumonia.</p><p class="headingAnchor" id="H26"><span class="h1">SELECTION OF INITIAL THERAPY</span><span class="headingEndMark"> — </span>In practice, most initial therapy is empiric while awaiting diagnostic studies. However, with careful attention to individual patient characteristics, a limited differential diagnosis can be established and empiric antibiotic therapy tailored to treat the most likely pathogens and minimize toxicity and cost. This may also avoid unnecessary broad-spectrum antimicrobial coverage. Antimicrobial agents used for prophylaxis should be avoided in empiric therapy as resistance may emerge.</p><p>The management of specific infections is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Empiric treatment of patients with febrile neutropenia (see  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Community-acquired pneumonia (see  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospital-acquired, ventilator-associated, and health care-associated pneumonia (see  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive aspergillosis (see  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Pneumocystis</em> pneumonia (see  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus pneumonitis [<a href="#rid116">116</a>] (see  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacterial infections (see  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a> and  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections in lung transplant recipients (see  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>)</p><p></p><p class="headingAnchor" id="H882523"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The spectrum of immunocompromised hosts has expanded with prolonged survival for solid organ and hematopoietic cell transplant recipients, patients with immune deficiencies (including congenital disorders and HIV/AIDS), cancers, and autoimmune disorders. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of infection in immunocompromised hosts is often delayed because the usual signs of infection are missing due to the muted inflammatory response. The differential diagnosis of pulmonary infiltrates in immunocompromised patients is broad and includes both infectious and noninfectious conditions. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Novel immunosuppressive therapies create a diverse set of immune deficits that create the substrate for opportunistic infections. These patients are defined by their susceptibility to infection with organisms of low native virulence for immunologically normal hosts. Pulmonary infection remains the most common form of tissue-invasive infection in these hosts. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical presentations and radiologic findings may be amplified by immunomodulatory therapies (eg, checkpoint inhibitors or chimeric antigen receptor-modified T [CAR-T] cells) and immune reconstitution (highly active antiretroviral therapy in HIV, stem cell engraftment).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early diagnosis and specific therapy of opportunistic infections is the cornerstone of successful treatment. The general rule is to be aggressive in pursuing a specific microbiologic diagnosis in immunocompromised patients with pulmonary infiltrates to avoid overly broad antimicrobial therapy; invasive diagnostic techniques are often required. (See <a class="local">'General principles'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence and severity of pneumonia vary with the characteristics of the affected individual, including the nature of the immune deficits  (<a class="graphic graphic_table graphicRef57336" href="/z/d/graphic/57336.html" rel="external">table 1</a>) and epidemiologic exposures. Aspiration remains an important source of pulmonary infection in all immunocompromised patients. (See <a class="local">'Epidemiology and risk of pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most immunocompromised patients with any sign of possible invasive infection including rigors or hypotension should be hospitalized for evaluation. The differential diagnosis of pulmonary infiltrates in immunocompromised patients is broad and includes both infectious and noninfectious conditions. (See <a class="local">'General principles'</a> above and <a class="local">'Hospital admission'</a> above.)</p><p></p><p class="bulletIndent1">Certain subgroups of immunocompromised patients are highly susceptible to infection. These include patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive tumors (eg, new leukemia or lymphoma or uncontrolled metastatic cancer)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recent hematopoietic cell transplant (HCT), matched unrelated HCT (MUD), umbilical cord HCT, and allogeneic HCT recipients with significant graft-versus-host disease (GVHD)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recent infections, especially due to cytomegalovirus (CMV) or respiratory viruses, or with known colonization with fungi or resistant bacteria</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absolute neutrophil count (ANC) below 500/microL, and especially those below 100/microL, or those in whom the ANC is falling rapidly or expected to fall below 100/microL</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-dose glucocorticoid therapy or recent intensification of immunosuppression (eg, in solid organ transplant recipients being treated for rejection)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence or absence of pulmonary infiltrates should be defined by chest radiography or computed tomography (CT) scan. The pattern of involvement can be helpful in establishing the etiology of the process. Routine chest radiograph is not sufficient to exclude pulmonary involvement if there are any respiratory symptoms or historical features that suggest a possible pulmonary process. The threshold for performing a chest CT should be low in immunocompromised hosts. (See <a class="local">'Radiologic clues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive procedures are frequently required to obtain tissue or sputum in order to make a specific diagnosis. These are best considered early in the clinical course. (See <a class="local">'Invasive procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most initial therapy is empiric while awaiting diagnostic studies. With attention to individual patient characteristics, a limited differential diagnosis can be established and empiric antibiotic therapy tailored to treat the most likely pathogens and minimize toxicity and cost. This may also avoid unnecessary broad-spectrum antimicrobial coverage. (See <a class="local">'Selection of initial therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H1127348056"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Masur H, Shelhamer J, Parrillo JE. The management of pneumonias in immunocompromised patients. JAMA 1985; 253:1769.</a></li><li><a class="nounderline abstract_t">Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore) 1980; 59:206.</a></li><li><a class="nounderline abstract_t">Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.</a></li><li class="breakAll">Greene R. The radiology of pulmonary infection. In: Fishman's Pulmonary Diseases and Disorders, 4th, Fishman AP, Elias JA, Fishman JA, et al (Eds), McGraw-Hill, New York 2008. p.2017.</li><li><a class="nounderline abstract_t">Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017; 17:856.</a></li><li><a class="nounderline abstract_t">Fishman JA, Dey BR, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2004. A 58-year-old man with acute myeloid leukemia and Fever after chemotherapy. N Engl J Med 2004; 350:1339.</a></li><li><a class="nounderline abstract_t">Costa SF, Alexander BD. Non-Aspergillus fungal pneumonia in transplant recipients. Clin Chest Med 2005; 26:675.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.</a></li><li><a class="nounderline abstract_t">Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.</a></li><li><a class="nounderline abstract_t">Carlisle PS, Gucalp R, Wiernik PH. Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 1993; 14:320.</a></li><li><a class="nounderline abstract_t">Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1296.</a></li><li><a class="nounderline abstract_t">Hammond SP, Marty FM, Bryar JM, et al. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol 2010; 85:695.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10:1412.</a></li><li><a class="nounderline abstract_t">Pagano L, Caira M, Rossi G, et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol 2012; 91:767.</a></li><li><a class="nounderline abstract_t">Dettenkofer M, Wenzler-Röttele S, Babikir R, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis 2005; 40:926.</a></li><li><a class="nounderline abstract_t">Aguilar-Guisado M, Jiménez-Jambrina M, Espigado I, et al. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clin Transplant 2011; 25:E629.</a></li><li><a class="nounderline abstract_t">Evans SE, Ost DE. Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med 2015; 21:260.</a></li><li><a class="nounderline abstract_t">Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012; 54:470.</a></li><li><a class="nounderline abstract_t">Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101.</a></li><li><a class="nounderline abstract_t">Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9:835.</a></li><li><a class="nounderline abstract_t">Girmenia C, Busca A, Candoni A, et al. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. Med Mycol 2019; 57:S127.</a></li><li><a class="nounderline abstract_t">Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clin Infect Dis 2018; 67:1621.</a></li><li><a class="nounderline abstract_t">Tada K, Kurosawa S, Hiramoto N, et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant 2013; 48:74.</a></li><li><a class="nounderline abstract_t">Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893.</a></li><li><a class="nounderline abstract_t">Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant 1995; 16:175.</a></li><li><a class="nounderline abstract_t">Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20:1490.</a></li><li><a class="nounderline abstract_t">Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13:R139.</a></li><li><a class="nounderline abstract_t">Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.</a></li><li><a class="nounderline abstract_t">Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.</a></li><li><a class="nounderline abstract_t">Díaz-Ravetllat V, Greer M, Haverich A, et al. Significance of new lung infiltrates in outpatients after lung and heart-lung transplantation. Transpl Infect Dis 2014; 16:359.</a></li><li><a class="nounderline abstract_t">Anesi JA, Baddley JW. Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection. Infect Dis Clin North Am 2016; 30:277.</a></li><li><a class="nounderline abstract_t">Gavaldà J, Meije Y, Fortún J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 Suppl 7:27.</a></li><li><a class="nounderline abstract_t">Herrera S, Husain S. Early diagnosis of fungal infections in lung transplant recipients, colonization versus invasive disease? Curr Opin Organ Transplant 2018; 23:381.</a></li><li><a class="nounderline abstract_t">Lemonovich TL. Mold Infections in Solid Organ Transplant Recipients. Infect Dis Clin North Am 2018; 32:687.</a></li><li><a class="nounderline abstract_t">Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13587.</a></li><li><a class="nounderline abstract_t">Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77:1215.</a></li><li><a class="nounderline abstract_t">Giannella M, Muñoz P, Alarcón JM, et al. Pneumonia in solid organ transplant recipients: a prospective multicenter study. Transpl Infect Dis 2014; 16:232.</a></li><li><a class="nounderline abstract_t">Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis 2019; 69:909.</a></li><li><a class="nounderline abstract_t">Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One 2016; 11:e0160221.</a></li><li><a class="nounderline abstract_t">Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378:158.</a></li><li><a class="nounderline abstract_t">Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54:139.</a></li><li><a class="nounderline abstract_t">Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018; 131:121.</a></li><li><a class="nounderline abstract_t">Park JH, Romero FA, Taur Y, et al. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 2018; 67:533.</a></li><li><a class="nounderline abstract_t">Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 2014; 58:1587.</a></li><li><a class="nounderline abstract_t">Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018; 131:1955.</a></li><li><a class="nounderline abstract_t">Busque S, Vincenti FG, Tedesco Silva H, et al. Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. Transplant Direct 2018; 4:e380.</a></li><li><a class="nounderline abstract_t">Sen P, Wilkie AR, Ji F, et al. Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function. Sci Adv 2020; 6:eaax9856.</a></li><li><a class="nounderline abstract_t">Marr KA, Platt A, Tornheim JA, et al. Aspergillosis Complicating Severe Coronavirus Disease. Emerg Infect Dis 2021; 27.</a></li><li><a class="nounderline abstract_t">Rosenow EC 3rd, Wilson WR, Cockerill FR 3rd. Pulmonary disease in the immunocompromised host. 1. Mayo Clin Proc 1985; 60:473.</a></li><li><a class="nounderline abstract_t">Rosenow EC 3rd. Diffuse pulmonary infiltrates in the immunocompromised host. Clin Chest Med 1990; 11:55.</a></li><li><a class="nounderline abstract_t">Bodey GP, Rodriguez V, Chang HY, Narboni . Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978; 41:1610.</a></li><li><a class="nounderline abstract_t">HERSH EM, BODEY GP, NIES BA, FREIREICH EJ. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA 1965; 193:105.</a></li><li><a class="nounderline abstract_t">Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993; 7:771.</a></li><li><a class="nounderline abstract_t">Coker DD, Morris DM, Coleman JJ, et al. Infection among 210 patients with surgically staged Hodgkin's disease. Am J Med 1983; 75:97.</a></li><li><a class="nounderline abstract_t">Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.</a></li><li><a class="nounderline abstract_t">Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clin Infect Dis 2019; 68:1482.</a></li><li><a class="nounderline abstract_t">Rañó A, Agustí C, Jimenez P, et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax 2001; 56:379.</a></li><li><a class="nounderline abstract_t">Shorr AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004; 125:260.</a></li><li><a class="nounderline abstract_t">Danés C, González-Martín J, Pumarola T, et al. Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol. J Clin Microbiol 2002; 40:2134.</a></li><li><a class="nounderline abstract_t">Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010; 24:439.</a></li><li><a class="nounderline abstract_t">Shoham S. Emerging fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27:305.</a></li><li><a class="nounderline abstract_t">Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8:512.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.</a></li><li><a class="nounderline abstract_t">Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139.</a></li><li><a class="nounderline abstract_t">Alangaden GJ, Wahiduzzaman M, Chandrasekar PH, Bone Marrow Transplant Group. Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 2002; 35:659.</a></li><li><a class="nounderline abstract_t">Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.</a></li><li><a class="nounderline abstract_t">Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27:877.</a></li><li><a class="nounderline abstract_t">Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28:618.</a></li><li><a class="nounderline abstract_t">Escuissato DL, Warszawiak D, Marchiori E. Differential diagnosis of diffuse alveolar haemorrhage in immunocompromised patients. Curr Opin Infect Dis 2015; 28:337.</a></li><li><a class="nounderline abstract_t">Bergeron A. Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017; 38:249.</a></li><li><a class="nounderline abstract_t">Vande Vusse LK, Madtes DK. Early Onset Noninfectious Pulmonary Syndromes after Hematopoietic Cell Transplantation. Clin Chest Med 2017; 38:233.</a></li><li><a class="nounderline abstract_t">White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med 2000; 161:723.</a></li><li><a class="nounderline abstract_t">Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006; 25:241.</a></li><li><a class="nounderline abstract_t">Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102:2777.</a></li><li><a class="nounderline abstract_t">Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2017; 35:709.</a></li><li><a class="nounderline abstract_t">Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2:1607.</a></li><li><a class="nounderline abstract_t">Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res 2016; 22:6051.</a></li><li><a class="nounderline abstract_t">Del Castillo M, Romero FA, Argüello E, et al. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Clin Infect Dis 2016; 63:1490.</a></li><li><a class="nounderline abstract_t">Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv119.</a></li><li><a class="nounderline abstract_t">Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1714.</a></li><li><a class="nounderline abstract_t">Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005; 26:691.</a></li><li><a class="nounderline abstract_t">Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26:834.</a></li><li><a class="nounderline abstract_t">Rossen JWA, Friedrich AW, Moran-Gilad J, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD). Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. Clin Microbiol Infect 2018; 24:355.</a></li><li><a class="nounderline abstract_t">Reynolds JH, Banerjee AK. Imaging pneumonia in immunocompetent and immunocompromised individuals. Curr Opin Pulm Med 2012; 18:194.</a></li><li><a class="nounderline abstract_t">Kunihiro Y, Tanaka N, Kawano R, et al. Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography. Eur Radiol 2019; 29:6089.</a></li><li><a class="nounderline abstract_t">Donowitz GR, Harman C, Pope T, Stewart FM. The role of the chest roentgenogram in febrile neutropenic patients. Arch Intern Med 1991; 151:701.</a></li><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:433.</a></li><li class="breakAll">Greene R. Transthoracic needle aspiration biopsy. In: International Radiology, Athanazoulis C, Pfister R, Greene R, et al (Eds), WB Saunders, Philadelphia 1981. p.587.</li><li><a class="nounderline abstract_t">Jaffe JP, Maki DG. Lung biopsy in immunocompromised patients: one institution's experience and an approach to management of pulmonary disease in the compromised host. Cancer 1981; 48:1144.</a></li><li><a class="nounderline abstract_t">Janzen DL, Adler BD, Padley SP, Müller NL. Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pulmonary disease: predictive value of disease distribution as shown on CT. AJR Am J Roentgenol 1993; 160:21.</a></li><li><a class="nounderline abstract_t">McKenna RJ Jr, Mountain CF, McMurtrey MJ. Open lung biopsy in immunocompromised patients. Chest 1984; 86:671.</a></li><li><a class="nounderline abstract_t">Toledo-Pereyra LH, DeMeester TR, Kinealey A, et al. The benefits of open lung biopsy in patients with previous non-diagnostic transbronchial lung biopsy. A guide to appropriate therapy. Chest 1980; 77:647.</a></li><li><a class="nounderline abstract_t">Westcott JL. Percutaneous transthoracic needle biopsy. Radiology 1988; 169:593.</a></li><li><a class="nounderline abstract_t">Scott WW Jr, Kuhlman JE. Focal pulmonary lesions in patients with AIDS: percutaneous transthoracic needle biopsy. Radiology 1991; 180:419.</a></li><li><a class="nounderline abstract_t">Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:647.</a></li><li><a class="nounderline abstract_t">Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol 2015; 33:501.</a></li><li><a class="nounderline abstract_t">Moore EH, Shepard JA, McLoud TC, et al. Positional precautions in needle aspiration lung biopsy. Radiology 1990; 175:733.</a></li><li><a class="nounderline abstract_t">Naidich DP, Sussman R, Kutcher WL, et al. Solitary pulmonary nodules. CT-bronchoscopic correlation. Chest 1988; 93:595.</a></li><li><a class="nounderline abstract_t">Perlmutt LM, Johnston WW, Dunnick NR. Percutaneous transthoracic needle aspiration: a review. AJR Am J Roentgenol 1989; 152:451.</a></li><li><a class="nounderline abstract_t">Plunkett MB, Peterson MS, Landreneau RJ, et al. Peripheral pulmonary nodules: preoperative percutaneous needle localization with CT guidance. Radiology 1992; 185:274.</a></li><li><a class="nounderline abstract_t">Brownback KR, Thomas LA, Simpson SQ. Role of bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in immunocompromised patients. Curr Opin Infect Dis 2014; 27:322.</a></li><li><a class="nounderline abstract_t">Maschmeyer G, Donnelly JP. How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. Br J Haematol 2016; 173:179.</a></li><li><a class="nounderline abstract_t">Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762.</a></li><li><a class="nounderline abstract_t">Hummel M, Rudert S, Hof H, et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008; 87:291.</a></li><li><a class="nounderline abstract_t">Fishman JA, Roth RS, Zanzot E, et al. Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii. J Clin Microbiol 1994; 32:131.</a></li><li><a class="nounderline abstract_t">Joos L, Chhajed PN, Wallner J, et al. Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients. Respir Med 2007; 101:93.</a></li><li><a class="nounderline abstract_t">Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45:1759.</a></li><li><a class="nounderline abstract_t">Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012; 89:120.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP. Rational approach to pulmonary infiltrates in leukemia and transplantation. Best Pract Res Clin Haematol 2013; 26:301.</a></li><li><a class="nounderline abstract_t">Fortún J, Martín-Dávila P, Gomez Garcia de la Pedrosa E, et al. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. J Infect 2016; 72:738.</a></li><li><a class="nounderline abstract_t">Zinter MS, Dvorak CC, Mayday MY, et al. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children. Clin Infect Dis 2019; 68:1847.</a></li><li><a class="nounderline abstract_t">Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018; 102:900.</a></li></ol></div><div id="topicVersionRevision">Topic 1401 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3974057" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The management of pneumonias in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6997674" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589125" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070821" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pulmonary complications of solid organ and hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117944" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infection in Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2004. A 58-year-old man with acute myeloid leukemia and Fever after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Non-Aspergillus fungal pneumonia in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880955" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5216294" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8360462" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nosocomial infections in neutropenic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968824" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652970" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Invasive fungal disease in patients treated for newly diagnosed acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138169" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention and treatment of cancer-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124621" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A prospective survey of febrile events in hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824981" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150886" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784246" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pneumonia in the neutropenic cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109954" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218876" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344469" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30816979" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860307" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22635245" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436099" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Engraftment syndrome following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581119" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148074" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumocystis jirovecii pneumonia in patients with or without AIDS, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21884589" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207081" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Infectious complications of antilymphocyte therapies in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466271" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infectious complications associated with immunomodulating biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24725092" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Significance of new lung infiltrates in outpatients after lung and heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26739603" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24810152" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Invasive fungal infections in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794553" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early diagnosis of fungal infections in lung transplant recipients, colonization versus invasive disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146030" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mold Infections in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077616" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114088" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sirolimus-associated pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24593292" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pneumonia in solid organ transplant recipients: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30520987" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472273" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320654" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765102" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immune-related adverse events with immune checkpoint blockade: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29038338" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481659" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585557" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437588" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30234149" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32494628" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084566" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Aspergillosis Complicating Severe Coronavirus Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2409412" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pulmonary disease in the immunocompromised host. 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182278" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diffuse pulmonary infiltrates in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/346201" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fever and infection in leukemic patients: a study of 494 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14304351" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354656" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evolving risk factors for infectious complications of cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859090" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infection among 210 patients with surgically staged Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1052668" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical presentation of infection in granulocytopenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222287" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718449" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037077" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466278" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fungal infections in transplant and oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23714342" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Emerging fungal infections in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374456" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393425" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715308" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203161" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731939" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477447" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194088" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26098496" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Differential diagnosis of diffuse alveolar haemorrhage in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477637" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477636" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Early Onset Noninfectious Pulmonary Syndromes after Hematopoietic Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10712314" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The utility of open lung biopsy in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446228" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Reversible sirolimus-associated pneumonitis after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855568" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27646942" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540850" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535979" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27501841" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881921" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29442540" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263406" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cytomegalovirus pneumonia in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692788" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117578" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388581" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Imaging pneumonia in immunocompetent and immunocompromised individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062135" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012451" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The role of the chest roentgenogram in febrile neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27481947" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27481947" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7272948" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lung biopsy in immunocompromised patients: one institution's experience and an approach to management of pulmonary disease in the compromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416634" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pulmonary disease: predictive value of disease distribution as shown on CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6488902" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Open lung biopsy in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7363683" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The benefits of open lung biopsy in patients with previous non-diagnostic transbronchial lung biopsy. A guide to appropriate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055026" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Percutaneous transthoracic needle biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068304" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Focal pulmonary lesions in patients with AIDS: percutaneous transthoracic needle biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684637" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559816" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2343123" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Positional precautions in needle aspiration lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3342671" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Solitary pulmonary nodules. CT-bronchoscopic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644771" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Percutaneous transthoracic needle aspiration: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1523323" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Peripheral pulmonary nodules: preoperative percutaneous needle localization with CT guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24977681" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Role of bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26729577" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909264" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932672" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126167" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740381" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886801" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428933" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22650156" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309535" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Rational approach to pulmonary infiltrates in leukemia and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025205" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30239621" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596116" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
